Study S000333

A Single Centre, Randomised, Double-blind, Placebo Controlled Trial to Evaluate the Possible Drug-drug Interaction Between Liraglutide and Paracetamol and the Effects of Liraglutide on Postprandial Glucose and Insulin, Gastric Emptying, Appetite Sensations and Energy Intake in Subjects With Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT01517555
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 18
Start: 2006-10
Primary completion: 2007-05
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:liraglutide; DRUG:placebo; DRUG:paracetamol
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2006-000561-10

Registered primary outcomes

Area under the curve of paracetamol []
Area under the curve of post prandial plasma glucose []

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0019046	The Effects of a GLP-1 Analog on Glucose Homeostasis in Type 2 Diabetes Mellitus Quantified by an Integrated Glucose Insulin Model. Røge RM, CPT: pharmacometrics & systems pharmacology	2015	Other	PMID 26225223 DOI	registry reference RESULT:26225223
R0023875	The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment. Flint A, Diabetes, obesity & metabolism	2013	Randomized trial	PMID 23551925 DOI	registry reference RESULT:23551925
R0024203	The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen. Kapitza C, Advances in therapy	2011	Randomized trial	PMID 21792552 DOI	registry reference RESULT:21792552
R0025338	The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Flint A, Advances in therapy	2011	Randomized trial	PMID 21340616 DOI	registry reference RESULT:21340616